Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01499381 · ClinicalTrials.gov registry record
EMBRACE1: Prostate Biorepository
A clinical trial, sponsored by Caris Science.
- Completed
- Registry status
- 1,290
- Enrollment target
NCT01499381: Completed study, sponsored by Caris Science.
NCT01499381 is a clinical trial that has completed, run by Caris Science. The registered enrollment target is 1,290 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01499381 has completed, sponsored by Caris Science.
- COMPLETED
- Registry status
- 1,290 participants
- Enrollment target
Study Summary
The objective of this multi-center prospective observational clinical study is to evaluate the clinical performance of the Carisome Prostate assay as an aid in the diagnosis of prostate cancer in men that have been scheduled for a prostate biopsy. Primarily, results of the Carisome Prostate assay will be compared with pathology results of prostate biopsy procedures. Secondarily, the performance of the Carisome Prostate test will be compared to the current standard of care for the detection of prostate cancer.
Primary Outcome
Association of Carisome Prostate Assay result with prostate biopsy outcome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,290 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-07 |
What the finished NCT01499381 record still lists
NCT01499381 is an observational study that tracks outcomes without assigning an intervention. Its 1,290 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01499381 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01499381 about?
NCT01499381 is a clinical study titled "EMBRACE1: Prostate Biorepository". The objective of this multi-center prospective observational clinical study is to evaluate the clinical performance of the Carisome Prostate assay as an aid in the diagnosis of prostate cancer in men that have been scheduled for a prostate biopsy. Primarily, results of the Carisome Prostate assay wi...
What is the current status of trial NCT01499381?
This trial is currently completed. The enrollment target is 1,290 participants. The study started on 2011-12. Estimated completion is 2012-07.
Who is sponsoring clinical trial NCT01499381?
This trial is sponsored by Caris Science, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05595642 · 1,290 participants · Phase 3
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
- NCT05812807 · 1,295 participants · Phase 3
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
- NCT06626022 · 1,284 participants · Phase 3
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
- NCT04474223 · 1,300 participants · Phase 3
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia